Cancer prevention research (Philadelphia, Pa.)最新文献

{"title":"Discovery and validation of molecular biomarkers for differentiation of non-dysplastic Barrett esophagus from high-grade dysplasia and esophageal adenocarcinoma.","authors":"Caroline L Matchett, Seth W Slettedahl, William R Taylor, Calise K Berger, Caryn E Anderson, Melissa A Passe, Ramona M Lansing, Panwen Wang, Collin E Chalmers, Patrick H Foote, Jeanette E Eckel-Passow, Zhifu Sun, Douglas W Mahoney, D Chamil Codipilly, Cadman L Leggett, Francisco C Ramirez, Allon Kahn, Herbert C Wolfsen, Swathi Eluri, Vani J A Konda, Arvind J Trindade, Prasad G Iyer, John B Kisiel","doi":"10.1158/1940-6207.CAPR-25-0215","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0215","url":null,"abstract":"<p><p>Aberrant DNA methylation and copy number alterations (CNAs) drive Barrett's esophagus (BE) progression to esophageal adenocarcinoma (EAC); however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDMs) and CNAs to distinguish EAC/high-grade dysplasia (HGD) from non-dysplastic Barrett's esophagus (NDBE). In this multi-phase, multi-center study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing data set obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N=18) and EAC (N=18) versus NDBE brushing samples (N=18) were tested in independent samples (N=146). A 52-MDM panel achieved a cross-validated area under the receiver operating characteristic curve (AUC) 0.88 (95% CI: 0.82-0.95); the addition of AS improved discrimination of HGD/EAC from NDBE to 0.91 (95% CI: 0.86-0.97) AUC. At 80% specificity, the combined model detected 93% of EAC and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI: 0.66-0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI: 0.7-0.9). MDMs and AS discerned HGD/EAC from normal esophagus (NE)/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve BE surveillance.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels.","authors":"Aiwu Ruth He, Coleman I Smith, Marcia Cruz-Correa, Richik Chakraborty, Shuwei Zhang, Shengmin Sang, Guang Cheng, Stephen S Hecht, Latifa A Bazzi, Masha Kocherginsky, Kelly A Benante, Tia Schering, Ellen Richmond, Luz Maria Rodriguez, Seema A Khan, Fung-Lung Chung","doi":"10.1158/1940-6207.CAPR-24-0526","DOIUrl":"10.1158/1940-6207.CAPR-24-0526","url":null,"abstract":"<p><p>Accumulation of the DNA adduct γ-hydroxy-1,N2-propanodeoxyguanosine (γ-OHPdG) is associated with hepatocellular carcinoma development. Theaphenon E-a green tea polyphenol extract dosed according to mg of epigallocatechin gallate-suppresses the formation of γ-OHPdG and reduces hepatocellular carcinoma development in preclinical models. This study aimed to evaluate the safety of Polyphenon E (Theaphenon E equivalent) and its effect on liver γ-OHPdG levels in patients with cirrhosis. This phase I trial used a 3 + 3 dose-escalation design with five planned Polyphenon E (epigallocatechin gallate) dose levels: 400, 800, 1,200, 1,600, and 2,000 mg daily, administered orally for 24 weeks. Each dose cohort was monitored for \"discontinue therapy\" criteria for 4 weeks before additional participants were enrolled in the next cohort. Participant liver samples were assessed for γ-OHPdG levels using LC/MS-MS and vibration-controlled transient elastography; endogenous catechin pharmacokinetic data were analyzed. Grade 1 and 2 treatment-related adverse events were observed in 38% of the participants. Liver γ-OHPdG levels declined after treatment in most participants. There was a decrease in the vibration-controlled transient elastography-controlled attenuation parameter in some participants. After Polyphenon E dosing, catechin pharmacokinetic clearance patterns were equivalent for all doses except 1,600 mg. Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. Therefore, the recommended starting dose for a phase II trial in a cirrhotic population is 1,200 mg. We observed promising Polyphenon E suppression of liver γ-OHPdG levels.</p><p><strong>Prevention relevance: </strong>In this phase I dose-escalation trial, Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. We observed promising Polyphenon E suppression of liver γ-OHPdG levels and recommend 1,200 mg dose for a future phase II trial in a cirrhotic population.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"635-646"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Maternal Epigenetic Regulation Contributes to Prevention of Estrogen Receptor-negative Mammary Cancer with Broccoli Sprout Consumption.","authors":"Shizhao Li, Min Chen, Huixin Wu, Yuanyuan Li, Trygve O Tollefsbol","doi":"10.1158/1940-6207.CAPR-25-0249","DOIUrl":"10.1158/1940-6207.CAPR-25-0249","url":null,"abstract":"","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"647"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Standardization in the Pediatric Management of Hereditary Polyposis Syndromes.","authors":"Luigi Ricciardiello, Y Nancy You","doi":"10.1158/1940-6207.CAPR-25-0279","DOIUrl":"10.1158/1940-6207.CAPR-25-0279","url":null,"abstract":"<p><p>Hereditary polyposis syndromes are inherited disorders with high malignancy risk. Management entails early genetic testing, structured surveillance, and risk-informed surgical intervention, yet current practice lacks pediatric-specific standardization. We propose targeted solutions: adoption of pediatric-focused protocols, development of decision-support tools for surgery timing, creation of multidisciplinary pediatric centers, inclusion of psychosocial services and standardized transition programs for lifelong care, and investment in genotype-phenotype research and chemoprevention trials. Coordinated efforts are needed to enhance evidence-based, equitable pediatric hereditary polyposis syndrome care. See related article by Kurowski et al., p. 603.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"579-581"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Cervical Cancer Screening Acceptance among Women in Urban and Tribal Communities of Maharashtra, India: A Cross-sectional Study.","authors":"Kiran Munne, Prerana Patil, Anjali Mayekar, Shantanu Birje, Ganga Bhekare, Shahanara Prabhu Valawalkar, Anamika Akula, Varsha Tryambake, Sharmila Kamat, Rachna Dalvi, Deepti Tandon, Suchitra Surve, Shahina Begum, Madhuri Shikhare, Sharmila Pimple, Anushree Patil","doi":"10.1158/1940-6207.CAPR-25-0174","DOIUrl":"10.1158/1940-6207.CAPR-25-0174","url":null,"abstract":"<p><p>Although screening, treatment, and human papillomavirus vaccination can prevent cervical cancer, 17.7% new Indian cases were still recorded in 2022. Illiteracy, undesirable attitudes, and ineffective screening services undermine the effectiveness of cervical cancer screening. We evaluated the knowledge (K), attitude (A), and practices (P) toward cervical cancer and their influence on screening acceptance among urban and tribal women of Maharashtra, India. A cross-sectional study was conducted among 500 urban and 500 tribal women, recruited to equally represent both populations. KAP data on cervical cancer were collected using a structured questionnaire. Participants received free cervical cancer screening. KAP scores were calculated, and their associations with sociodemographic factors and cervical cancer screening were assessed using logistic regression. A total of 939 participants were enrolled. Considering both populations, a total of 530 (56%) participants were unaware about cervical cancer, 296 (72%) about its symptoms, and 250 (61%) of risk factors. Common misconceptions were that only women with symptoms of cervical cancer (166, 18%) or a family history of cervical cancer (385, 41%) needed screening. Fear of pain, bad result, and embarrassment were major perceived barriers. Whereas 65 (6.85%) participants had previously undergone screening, 756 (81%) desired screening and 670 (71.40%) underwent screening. Although women had limited cervical cancer knowledge, their attitude for screening is favorable. Generating awareness and implementing socioculturally acceptable strategies are crucial for amplifying cervical cancer screening among vulnerable women.</p><p><strong>Prevention relevance: </strong>Despite limited awareness and prevalent misconceptions about cervical cancer screening, the women expressed willingness to undergo screening following appropriate counseling. This highlights the potential for targeted educational interventions to enhance cervical cancer prevention through early detection and improving uptake of screening.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"615-624"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Practice of Hereditary Polyposis Syndromes in Children: A Survey of Providers Treating Pediatric Patients.","authors":"Jacob A Kurowski, Claudia Phen, David Liska, Marsha H Kay, Anthony L DeRoss, Sarah Worley, Carol A Burke, Thomas M Attard","doi":"10.1158/1940-6207.CAPR-25-0014","DOIUrl":"10.1158/1940-6207.CAPR-25-0014","url":null,"abstract":"<p><p>Data on the care of pediatric patients with hereditary polyposis syndromes (HPS) including familial adenomatous polyposis (FAP), juvenile polyposis syndrome, and Peutz-Jeghers syndrome are limited. We aim to describe the current practice patterns for HPS. An anonymous survey was distributed to pediatric gastroenterologists, pediatric surgeons, and adult colorectal surgeons. A total of 150 pediatric gastroenterologists and 129 surgeons started the survey, and 80 gastroenterologists and 70 surgeons completed the survey. A total of 62% of pediatric gastroenterologists identified that their clinical care most closely follows the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition position statement and 42% of surgeons reported following the National Comprehensive Cancer Network guidelines (P < 0.001). For gastroenterologists, 76% currently manage FAP (61% follow 1-5 patients) and 34% recommended genetic testing at birth or first presentation. At 10 to 14 years, 91% recommended initial colonoscopy. High-grade dysplasia (78%) was the most important factor for surgical referral for colectomy. A total of 43% reported documenting the number of rectal polyps and 31% referred to a surgeon for <50 polyps. Seventy-five percent manage juvenile polyposis syndrome and 56% manage Peutz-Jeghers syndrome. For surgeons, 81% currently manage FAP (56% follow 1-5 patients) and 68% follow patients <18 years. Twelve to 15 years was the most common age (47%) at colectomy. High-grade dysplasia (57%) was the most important factor for surgery. In the previous 12 months, 56% had not performed a colectomy. Ileal pouch-anal anastomosis was the most common reported surgery for FAP. Pediatric gastroenterologists and surgeons typically manage few pediatric patients with HPS, with significant heterogeneity and deviation from guidelines. Continued medical education is critical to standardizing care for pediatric HPS.</p><p><strong>Prevention relevance: </strong>Appropriate screening and surveillance in pediatric hereditary polyposis are critical in the early detection of intestinal cancers. See related Spotlight, p. 579.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"603-614"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect modification by levels of sex hormones in the association between adiposity and cancer incidence in the UK Biobank.","authors":"LeeAnn Lucas, Yujia Lu, Edward Giovannucci, Mingyang Song","doi":"10.1158/1940-6207.CAPR-25-0246","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-25-0246","url":null,"abstract":"<p><p>The role of sex hormones in the sex difference between adiposity and cancer risk remains unclear. We examined body mass index (BMI) and visceral adipose tissue (VAT) estimated using a validated equation in relation to cancer incidence according to serum sex hormone binding globulin (SHBG), testosterone, and estradiol among 451,500 UK Biobank participants. For cancers showing a sex-specific adiposity association, we used Cox regression to calculate multivariable hazard ratios (HR) per increase between the 10th to 90th percentiles of adiposity according to low versus high sex hormone levels. We documented 42,949 cancers over a median follow-up of 13.1 years. BMI and VAT were more strongly associated with a higher risk of esophageal, liver, and colorectal cancer in males than in females. In males, BMI showed a stronger association with esophageal (HR for high vs low SHBG = 2.38 vs 1.62, P-interaction = 0.04) and liver cancer (HR = 3.24 vs 1.96, P-interaction = 0.03) among those with high versus low SHBG, while an opposite pattern was observed for colorectal cancer (HR = 1.12 vs 1.47, P-interaction = 0.03). Among females, BMI was associated with a higher esophageal cancer risk in those with low (HR = 1.68) but not high SHBG (HR = 0.64, P-interaction = 0.025); for liver cancer, results were similar but statistically nonsignificant. No interaction by estradiol or testosterone was detected. Similar results were observed for VAT. SHBG may be an important factor underlying the sex difference in adiposity-associated risk for colorectal, esophageal, and liver cancer.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editors' Selections from Relevant Scientific Publications.","authors":"","doi":"10.1158/1940-6207.CAPR-18-10-HFL","DOIUrl":"https://doi.org/10.1158/1940-6207.CAPR-18-10-HFL","url":null,"abstract":"","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":"18 10","pages":"577"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Combination Early Detection to Multicancer Testing: Shifting Cancer Care toward Proactive Prevention and Interception.","authors":"Adriana Albini, Dario Trapani, Francesco Bertolini, Douglas M Noonan, Roberto Orecchia, Giovanni Corso","doi":"10.1158/1940-6207.CAPR-24-0558","DOIUrl":"10.1158/1940-6207.CAPR-24-0558","url":null,"abstract":"<p><p>Identifying the presence of tumors at a very early stage or deciphering the processes underlying their development can enable the interception of promalignant mechanisms underpinning cancer emergence, facilitating more effective prevention. Advances in molecular profiling allow the detection of genetic, epigenetic, immune, and microenvironmental alterations associated with cancer risk. Liquid biopsy permits noninvasive analysis of circulating tumor cells, nucleic acids, immune cells, extracellular vesicles, proteins, cytokines, and metabolites, whereas metagenome analysis facilitates gut microbiota profiling. Multicancer early detection assays broaden this approach, capturing signals from multiple malignancies using a single blood sample. These technologies go beyond genomics, addressing immune dysregulation and metabolic shifts, and may help identify gut microbiota imbalances. Clonal hematopoiesis of indeterminate potential is gaining increasing recognition as a biomarker. Cardiovascular risk scores based on multiple parameters are an inspiring example. The analysis of a combination of cancer drivers and enablers should provide a more sensitive and personalized measure of cancer prodromic profiles. Artificial intelligence will further support this transition by integrating molecular, immune, and metabolic data to develop individualized risk profiles. This shift from single-cancer detection to integrated, mechanism-based screening fosters a more proactive prevention model. This combination of early detection empowers cancer interception by using strategies, including lifestyle modification, nutritional optimization, drug repurposing, pharmacologic interventions, and targeted chemoprevention. Moving beyond single parameters analysis and organ-specific screening, this multidimensional approach advances early detection and interception as practical clinical goals, facilitating the fundamental aim of positioning prevention at the forefront of oncology.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"583-602"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use.","authors":"Lifang Li, Oscar Hou-In Chou, Kar Kei Mak, Yifan Yang, Cheuk To Chung, Guoliang Li, Catherine Po Ling Chan, Wing Tak Wong, Tong Liu, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou","doi":"10.1158/1940-6207.CAPR-24-0349","DOIUrl":"10.1158/1940-6207.CAPR-24-0349","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium-glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21-0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26-3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation.</p><p><strong>Prevention relevance: </strong>This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.</p>","PeriodicalId":72514,"journal":{"name":"Cancer prevention research (Philadelphia, Pa.)","volume":" ","pages":"625-634"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}